IRIS
CORALLO, SALVATORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.300
NA - Nord America 1.223
EU - Europa 685
SA - Sud America 203
AF - Africa 49
OC - Oceania 3
Totale 3.463
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.164
SG - Singapore 369
CN - Cina 322
HK - Hong Kong 189
IT - Italia 171
BD - Bangladesh 163
BR - Brasile 154
RU - Federazione Russa 149
VN - Vietnam 127
DE - Germania 107
FR - Francia 68
GB - Regno Unito 55
FI - Finlandia 35
IN - India 28
CA - Canada 25
PL - Polonia 23
ZA - Sudafrica 21
AR - Argentina 19
MX - Messico 19
AT - Austria 17
TR - Turchia 15
ES - Italia 12
IQ - Iraq 11
PK - Pakistan 10
NL - Olanda 9
EC - Ecuador 8
JP - Giappone 8
TN - Tunisia 8
CR - Costa Rica 7
MA - Marocco 7
SE - Svezia 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
ID - Indonesia 6
IL - Israele 5
MY - Malesia 5
PH - Filippine 5
UZ - Uzbekistan 5
VE - Venezuela 5
BA - Bosnia-Erzegovina 4
CL - Cile 4
KE - Kenya 4
LT - Lituania 4
TH - Thailandia 4
AO - Angola 3
AU - Australia 3
BE - Belgio 3
DO - Repubblica Dominicana 3
IE - Irlanda 3
JO - Giordania 3
NP - Nepal 3
PE - Perù 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
MM - Myanmar 2
MN - Mongolia 2
PY - Paraguay 2
RO - Romania 2
UA - Ucraina 2
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MT - Malta 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 3.463
Salva come PNG Salva come JPEG
Città #
San Jose 242
Hong Kong 183
Singapore 173
Dallas 169
Ashburn 128
Beijing 123
Council Bluffs 72
Los Angeles 57
Lauterbourg 49
Ho Chi Minh City 45
New York 38
Buffalo 35
Munich 34
Hanoi 32
Redondo Beach 31
Turku 28
Nuremberg 27
Santa Clara 21
São Paulo 21
Warsaw 20
Moscow 19
Johannesburg 18
Orem 18
Milan 17
Falkenstein 16
Denver 13
Rome 12
Mexico City 11
Atlanta 10
Boardman 10
Chicago 10
Da Nang 10
Düsseldorf 10
Montreal 10
Frankfurt am Main 9
Houston 9
London 9
Brooklyn 8
Tokyo 8
Cagliari 7
Chennai 7
Helsinki 7
Stockholm 7
Boston 6
Florence 6
Haiphong 6
Nova Milanese 6
Poplar 6
San Francisco 6
The Dalles 6
Vienna 6
Ankara 5
Belo Horizonte 5
Biên Hòa 5
Manchester 5
Naples 5
Pavia 5
Phoenix 5
Portsmouth 5
Rio de Janeiro 5
Seattle 5
Toronto 5
Bangkok 4
Hangzhou 4
Hyderabad 4
Oujda 4
San José 4
Secaucus 4
Tashkent 4
Amman 3
Amsterdam 3
Brasília 3
Brussels 3
Bến Tre 3
Changsha 3
Delhi 3
Desio 3
Dublin 3
Genoa 3
Kuala Lumpur 3
Londrina 3
Nairobi 3
Shanghai 3
Shijiazhuang 3
Tel Aviv 3
Tianjin 3
Vancouver 3
Zhoukou 3
Abu Dhabi 2
Addis Ababa 2
Almaty 2
Baku 2
Banja Luka 2
Bari 2
Bergamo 2
Biassono 2
Birmingham 2
Buenos Aires 2
Campinas 2
Caxias do Sul 2
Totale 1.995
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 148
Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei 115
Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS + HIPEC? 109
Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study 101
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 95
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study 94
First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study 88
Development, Expansion, and Histological Characterization of Patient-Derived Liver Organoids for Drug Screening and Disease Modeling 86
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 86
Chemotherapy-induced changes in plasma amino acids and lipid oxidation of resected patients with colorectal cancer: a background for future studies 82
Pink-on-pink: hepatocellular carcinoma metastatic to oncocytic carcinoma of the thyroid 81
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 79
Vaccine hesitancy in patients with solid tumors: a cross-sectional single-center survey 74
Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review 66
HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series 65
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer 65
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 64
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation 63
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 63
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial 62
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study 60
Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study 60
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 59
Adenomyoma/adenomyomatosis-associated mural intracholecystic neoplasms: analysis of clinico-pathologic, imaging, and molecular features of a consecutive case series 58
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 58
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality 56
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 55
Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification-A pooled analysis of TRIBE and TRIBE2 studies by GONO 55
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 55
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 53
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 53
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 52
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 52
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective 49
Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study 48
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 47
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer 44
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials 44
BRCA2-Related Hereditary Cancer Syndrome-Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature 43
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy 41
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan 41
Nutritional support management in resectable gastric cancer 41
Treatment options for EGFR T790M-negative egfr tyrosine kinase inhibitor-resistant non-small cell lung cancer 41
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial 41
The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition 40
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 38
Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca2+ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells 37
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases 37
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas 36
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO) 35
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 35
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 33
Mucinous cystic neoplasms of the liver: Literature review and case series 32
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 31
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 30
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 30
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 30
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 30
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study 29
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 29
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 28
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 25
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial 19
Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies 17
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come 13
Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence 7
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment 2
Interlesional genomic heterogeneity in small bowel adenocarcinoma: evidence from matched primary and peritoneal metastatic lesions 2
null 2
Totale 3.539
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.618
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 12 1 2 0 1 0 2 2 0 1 1 0
2024/2025866 1 1 29 2 51 61 100 47 217 61 90 206
2025/20262.651 163 145 150 321 276 122 346 102 273 239 352 162
Totale 3.539